Presentations
Differentiated & Potential Best-in-Class Bivalent RSV Vaccine Candidate (SCB-1019): Program Overview & Data Update- Clover Bio Potential Best-In-Class Bivalent RSV Vaccine Candidate SCB-1019_Phase I Results Head-to-Head Versus GSK (AREXVY)
- Clover Bio RSV Vaccine Candidate SCB-1019_0626 US ACIP Updates + Australia Phase I Older Adult Preliminary Data
- Clover Bio RSV Vaccine Candidate SCB-1019_Australia Phase I Preliminary Young Adult Data
- Clover Bio SCB-219M Preliminary Phase I data
